References
- Alkjaersig N., Fletcher A. P., Sherry S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (“fibrinolytic”) states. II. The significance, mechanism and consequences of defective polymerization. J. clin. Invest. 1962; 41: 917
- Blix S. The effectiveness of activators in clot lysis, with special reference to fibrinolytic therapy. Acta med. scand. 1962; 172
- Christensen L. R. Methods for measuring the activity of components of the streptococcal fibrinolytic system. J. clin. Invest. 1949; 28: 163
- Fletcher A. P., Alkjaersig N., Sherry S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (“fibrinolytic”) states. I. The significance of fibrinogen proteolysis and circulating fibrinogen break down products. Ibid. 1962; 41: 896
- Godal H. C., Helle I. In vitro studies on fibrinogenolysis induced by streptokinase. Scand. J. clin. Lab. Invest. 1963; 15: 303
- Konttinen Y. The effect of streptokinase on the plasma heparin thrombin time. Ibid. 1962; 14: 82
- Lassen M. Adsorption of plasminogen activator to fibrin. Acta chem. scand. 1958; 12: 1825
- Müllertz S., Lassen M. An activator system in blood indispensable for formation of plasmin by streptokinase. Proc. Soc. exp. Biol. (N.Y.) 1963; 82: 264
- Müllertz S. Formation and properties of the activator of plasminogen and of human and bovine plasmin. Biochem. J. 1955; 61: 424
- Burstein M., Guinand A. Mechanism of activation and effect of plasmin in blood. Acta physiol, scand. 1956; 38
- Troll W., Sherry S. The activation of human plasminogen by streptokinase. J. biol. Chem. 1955; 213: 881